Furthermore, these data demonstrate that such changes in the AGP structure caused by this BRAF kinase inhibitor can affect a global change in the cell surface glycosylation pattern that significantly alters melanoma cell growth, survival, and plausibly resistance performances. Here, ATP5MK is linked to melanoma.